Pages that link to "Q45759076"
Jump to navigation
Jump to search
The following pages link to A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum (Q45759076):
Displaying 50 items.
- Alpha-interferon for chronic hepatitis B (Q24236641) (← links)
- Alpha-interferon for chronic hepatitis B (Q24240563) (← links)
- The role of interferon therapy in hepatitis B (Q24529082) (← links)
- Hepatitis B virus: inactive carriers (Q24810833) (← links)
- Molecular cancer prevention: Current status and future directions (Q26797207) (← links)
- Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group (Q28370506) (← links)
- Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis (Q31431612) (← links)
- Naturally occurring variants of hepatitis B virus (Q33671155) (← links)
- Tickling the TLR7 to cure viral hepatitis (Q33690260) (← links)
- Antiviral therapy and resistance with hepatitis B virus infection (Q33787531) (← links)
- Management of viral hepatitis B. (Q33959006) (← links)
- Interferon monotherapy in chronic hepatitis B. (Q33988044) (← links)
- Precise prediction model and simplified scoring system for sustained combined response to interferon-alpha (Q33998692) (← links)
- Chronic hepatitis B. (Q34002160) (← links)
- Therapeutic management of hepatitis B-related cirrhosis (Q34434784) (← links)
- Current management strategies for hepatitis B in the elderly (Q34458425) (← links)
- Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. (Q34863403) (← links)
- A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection (Q34716850) (← links)
- Slowing the progression of chronic hepatitis B. Early antiviral therapy can help minimize complications (Q35182686) (← links)
- Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection (Q35568019) (← links)
- Natural history of hepatitis B. (Q35621647) (← links)
- Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon (Q35621713) (← links)
- Treatment options in HBV. (Q36342873) (← links)
- Update of research and management of hepatitis B. (Q36433765) (← links)
- Management of patients with HBeAg-negative chronic hepatitis B (Q36724421) (← links)
- Future prospectives for the management of chronic hepatitis B. (Q36841719) (← links)
- Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced (Q37243531) (← links)
- Role of viral factors in the natural course and therapy of chronic hepatitis B. (Q37280144) (← links)
- Interferons and their use in persistent viral infections (Q37338989) (← links)
- Liver biopsy findings in chronic hepatitis B. (Q37462537) (← links)
- SASLT practice guidelines for the management of hepatitis B virus. (Q37634822) (← links)
- Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration (Q37869826) (← links)
- Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? (Q38071402) (← links)
- HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? (Q38174261) (← links)
- Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility (Q38177851) (← links)
- Prevention of hepatitis B virus-associated liver diseases by antiviral therapy (Q38793117) (← links)
- RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells (Q40217527) (← links)
- Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. (Q42032030) (← links)
- Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. (Q42130644) (← links)
- IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. (Q42979018) (← links)
- Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers (Q43179682) (← links)
- Efficacy of interferon (conventional, pegylated) and lamivudine for treatment of chronic hepatitis B: a systematic review (Q43299772) (← links)
- Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan (Q43795952) (← links)
- Recent progress and new trends in the treatment of hepatitis B. (Q44062995) (← links)
- Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. (Q44475703) (← links)
- Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine (Q45070061) (← links)
- Interferon and lamivudine monotherapy on chronic hepatitis B in Japan (Q45274836) (← links)
- Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. (Q45359396) (← links)
- Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection (Q45736671) (← links)
- Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha. (Q45752264) (← links)